Corline Biomedical Résultats passés
Passé contrôle des critères 0/6
Corline Biomedical has been growing earnings at an average annual rate of 34.5%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 26.5% per year.
Informations clés
34.5%
Taux de croissance des bénéfices
40.2%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 30.5% |
Taux de croissance des recettes | 26.5% |
Rendement des fonds propres | -7.4% |
Marge nette | -22.4% |
Prochaine mise à jour des résultats | 07 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Aug 24We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Ventilation des recettes et des dépenses
Comment Corline Biomedical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 29 | -6 | 30 | 0 |
31 Mar 24 | 31 | -4 | 28 | 0 |
31 Dec 23 | 36 | -2 | 29 | 0 |
30 Sep 23 | 37 | -1 | 29 | 0 |
30 Jun 23 | 40 | 1 | 27 | 0 |
31 Mar 23 | 38 | 4 | 24 | 0 |
31 Dec 22 | 33 | 2 | 21 | 0 |
30 Sep 22 | 31 | 1 | 19 | 0 |
30 Jun 22 | 23 | -3 | 17 | 0 |
31 Mar 22 | 19 | -6 | 17 | 0 |
31 Dec 21 | 17 | -7 | 16 | 0 |
30 Sep 21 | 15 | -6 | 15 | 0 |
30 Jun 21 | 13 | -6 | 15 | 0 |
31 Mar 21 | 14 | -6 | 16 | 0 |
31 Dec 20 | 15 | -7 | 18 | 0 |
30 Sep 20 | 14 | -9 | 18 | 0 |
30 Jun 20 | 14 | -9 | 18 | 0 |
31 Mar 20 | 14 | -9 | 17 | 0 |
31 Dec 19 | 12 | -10 | 17 | 0 |
30 Sep 19 | 11 | -9 | 16 | 0 |
30 Jun 19 | 11 | -9 | 15 | 0 |
31 Mar 19 | 10 | -8 | 15 | 0 |
31 Dec 18 | 10 | -7 | 13 | 0 |
30 Sep 18 | 17 | -7 | 16 | 0 |
30 Jun 18 | 16 | -6 | 17 | 0 |
31 Mar 18 | 15 | -7 | 17 | 0 |
31 Dec 17 | 16 | -8 | 19 | 0 |
30 Sep 17 | 7 | -8 | 16 | 0 |
30 Jun 17 | 9 | -8 | 15 | 0 |
31 Mar 17 | 10 | -6 | 14 | 0 |
31 Dec 16 | 9 | -5 | 14 | 0 |
30 Sep 16 | 8 | -6 | 13 | 0 |
30 Jun 16 | 7 | -6 | 12 | 0 |
31 Mar 16 | 5 | -7 | 11 | 0 |
31 Dec 15 | 4 | -6 | 9 | 0 |
31 Dec 14 | 4 | -3 | 6 | 0 |
31 Dec 13 | 4 | -2 | 7 | 0 |
Des revenus de qualité: CLBIO is currently unprofitable.
Augmentation de la marge bénéficiaire: CLBIO is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CLBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 34.5% per year.
Accélération de la croissance: Unable to compare CLBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: CLBIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Rendement des fonds propres
ROE élevé: CLBIO has a negative Return on Equity (-7.38%), as it is currently unprofitable.